Researchers from Memorial Sloan Kettering Cancer Center (MSKCC) in New York have pioneered a new type of liquid biopsy that might be able to monitor the progression and response to treatment of a type of brain tumor. However, unlike most liquid biopsy tests to detect circulating tumor DNA (ctDNA), it does not use blood.

Read more at Forbes.